# OnCo record rejuv-recovery-endocrine-permanence (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-recovery-endocrine-permanence/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-recovery-endocrine-permanence" ;
  schema:name "Immune endocrine damage is usually permanent, and almost nobody is told"@en ;
  schema:description "Most immune side effects of checkpoint inhibitors settle. The hormone glands are the exception: a pituitary, thyroid, adrenal or insulin-making gland destroyed by the immune system does not grow back, and the replacement treatment that follows is usually for life. In the follow-up cohorts 83 per cent of hormone problems were still present three months after the drug stopped."@en ;
  schema:url <https://onco.cc/technologies/rejuv-recovery-endocrine-permanence/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hypophysitis> ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2021.0051>, <https://doi.org/10.1001/jamanetworkopen.2023.27145>, <https://doi.org/10.1111/cen.70137>, <https://doi.org/10.1089/thy.2021.0685>, <https://doi.org/10.3390/cancers14010089> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "evidence:strong", "late-effects", "irae" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/urothelial/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/rejuv-recovery-matrix/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:terms <https://onco.cc/terms/irae/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-survivorship/> .